Dr. Hausman is an Immunologist and Board-Certified Urological Surgeon with more than 30 years of drug research and development experience with various pharmaceutical companies, including Bristol-Myers International, Mead-Johnson Pharmaceutical Co., E.R. Squibb, Medco Research, and Axonyx.
He was a co-founder of Medco Research Inc., a NYSE listed clinical research organization and biotechnology company specializing in adenosine products that was subsequently acquired by King Pharmaceuticals. Dr. Hausman was also a co-founder of Axonyx, and served in various capacities as President, CEO and Chairman until the company merged into NASDAQ listed Torrey Pines Therapeutics Inc. in 2006. Dr. Hausman is currently a Director of NuGenerex Biotechnology Corporation and is Chairman of the Board of Directors and Chief Science and Technology Officer of Entia Biosciences Inc.
Dr. Hausman has done residencies in General Surgery at Mt. Sinai Hospital in New York, and in Urological Surgery at UCLA Medical Center. He received his medical degree from New York University School of Medicine.
He is on the Alumni Board of Governors of NYU Grossman School of Medicine.
Mr. Ivany has a rich history of successfully working with both start-up and publicly traded companies and has a track record of generating significant shareholder value.
Having worked with many internatinoal groups, Mr. Ivany has established a network of high-profile contacts across such sectors and medicinal and adult-use cannabis, oil & gas, mining, agriculture, technology, and e-sports.
Derek most recently stepped down as President and CEO of AgraFlora Organics International Inc. where, during his tenure, AGRA grew from under $2M in market capitalization to over $250M at its peak. Derek was instrumental in building AGRA’s asset base in both upstream and downstream cannabis operating entities including a licensed producer AAA Heidelberg in London, Ontario, and Propagation Services Canada in Delta, British Columbia which operates the 2nd largest cannabis greenhouse growing facility in the world measuring 2,200,000 square feet.
Derek has a special personal connection to autism. Derek’s brother Steve (1 year his junior), was diagnosed with ASD at a young age. Steve registers at the upper end of the ASD scale and is largely non-verbal. Derek has witnessed fist hand the devastating effects that severe autism can have on a family. Derek has been largely responsible for providing care and funding for Steve’s daily needs for the past 10 years and is passionate about doing his part in advancing research in this area.
Dr. Hochwimmer is chief analyst at General Research, GmbH, a leading Munich-based securities research and analysis firm. Dr. Georg Hochwimmer is a noted business consultant and academic responsible for aiding in the development of several highly profitable companies throughout Europe. He serves as CEO of supraMAT Technologies AG, which is a business incubator for German tech companies. He founded leading German tech start-ups such as Jenabatteries, SmartDyelivery and Trophosys. He is also a managing director of Microdrop Technologies which is a globally leading 3D micro-printing company. Dr. Hochwimmer has earned advanced degrees in chemistry and machinery engineering.
Specializing in early-stage technologies and data-driven corporate strategy, Dr. Perederiy holds scientific and commercialization expertise along the full spectrum of biological innovation, from single-cell analytics to systems-level therapeutics. An established academic scientist, Julia is an author of multiple peer-reviewed publications, including highly regarded research on the neurogenetics of autism. In the private sector, Julia is an experienced entrepreneur and management consultant, helping biotechnology companies with business planning, market entry strategy, and fundraising
Dr. Perederiy holds Bachelor’s degrees in Neurobiology and Psychology from the University of California, Berkeley, a Master’s in Technology Entrepreneurship from University of Portland, and a PhD in Neuroscience from Oregon Health & Science University.
Faculty at Roma Tre University in Rome, Italy, Dr. Trezza investigates the brain mechanisms underlying functional and dysfunctional socio-emotional behavior, with the long term of goal of identifying novel pharmacological targets for neuropsychiatric and neurodevelopmental disorders characterized by aberrant socio-emotional processing. A special emphasis in her studies is also placed on the role of the endocannabinoid system in the regulation of emotions and cognition through development.